Literature DB >> 33095444

Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Yair Herishanu1,2, Shai Levi1, Talia Kamdjou2, Yotam Bornstein1, Ron Ram1,2, Noam Benyamini1, David Varon1,3, Irit Avivi1,2, Chava Perry1,2.   

Abstract

Entities:  

Keywords:  AIHA; CLL; ITP; obinutuzumab

Year:  2020        PMID： 33095444     DOI： 10.1111/bjh.17105

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

Review 1.  Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.

Authors:  Jennifer R Blase; David Frame; Thomas F Michniacki; Kelly Walkovich
Journal:  Front Immunol       Date:  2022-04-19       Impact factor: 8.786

Review 2.  The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia.

Authors:  Alessandro Noto; Ramona Cassin; Veronica Mattiello; Gianluigi Reda
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.